180 related articles for article (PubMed ID: 29721202)
21. Circulating tumor cells as a biomarker predictive of sensitivity to docetaxel chemotherapy in patients with castration-resistant prostate cancer.
Okegawa T; Itaya N; Hara H; Tambo M; Nutahara K
Anticancer Res; 2014 Nov; 34(11):6705-10. PubMed ID: 25368278
[TBL] [Abstract][Full Text] [Related]
22. Limited prognostic value of preoperative circulating tumor cells for early biochemical recurrence in patients with localized prostate cancer.
Meyer CP; Pantel K; Tennstedt P; Stroelin P; Schlomm T; Heinzer H; Riethdorf S; Steuber T
Urol Oncol; 2016 May; 34(5):235.e11-6. PubMed ID: 26795608
[TBL] [Abstract][Full Text] [Related]
23. Can determination of circulating endothelial cells and serum caspase-cleaved CK18 predict for response and survival in patients with advanced non-small-cell lung cancer receiving endostatin and paclitaxel-carboplatin chemotherapy? a retrospective study.
Chu TQ; Ding H; Garfield DH; Gu AQ; Pei J; Du WD; Han BH
J Thorac Oncol; 2012 Dec; 7(12):1781-1789. PubMed ID: 23154549
[TBL] [Abstract][Full Text] [Related]
24. Molecular profiling of peripheral blood is associated with circulating tumor cells content and poor survival in metastatic castration-resistant prostate cancer.
Marín-Aguilera M; Reig Ò; Lozano JJ; Jiménez N; García-Recio S; Erill N; Gaba L; Tagliapietra A; Ortega V; Carrera G; Colomer A; Gascón P; Mellado B
Oncotarget; 2015 Apr; 6(12):10604-16. PubMed ID: 25871394
[TBL] [Abstract][Full Text] [Related]
25. Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience.
Olmos D; Arkenau HT; Ang JE; Ledaki I; Attard G; Carden CP; Reid AH; A'Hern R; Fong PC; Oomen NB; Molife R; Dearnaley D; Parker C; Terstappen LW; de Bono JS
Ann Oncol; 2009 Jan; 20(1):27-33. PubMed ID: 18695026
[TBL] [Abstract][Full Text] [Related]
26. Large tumour-derived extracellular vesicles as prognostic indicators of metastatic cancer patient survival.
Goberdhan DCI
Br J Cancer; 2023 Feb; 128(3):471-473. PubMed ID: 36385555
[TBL] [Abstract][Full Text] [Related]
27. mRNA expression profiles in circulating tumor cells of metastatic colorectal cancer patients.
Mostert B; Sieuwerts AM; Bolt-de Vries J; Kraan J; Lalmahomed Z; van Galen A; van der Spoel P; de Weerd V; Ramírez-Moreno R; Smid M; Verhoef C; IJzermans JN; Gratama JW; Sleijfer S; Foekens JA; Martens JW
Mol Oncol; 2015 Apr; 9(4):920-32. PubMed ID: 25655581
[TBL] [Abstract][Full Text] [Related]
28. Detection of extracellular vesicles in plasma and urine of prostate cancer patients by flow cytometry and surface plasmon resonance imaging.
Rikkert LG; de Rond L; van Dam A; van Leeuwen TG; Coumans FAW; de Reijke TM; Terstappen LWMM; Nieuwland R
PLoS One; 2020; 15(6):e0233443. PubMed ID: 32497056
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells.
Onstenk W; Sieuwerts AM; Kraan J; Van M; Nieuweboer AJ; Mathijssen RH; Hamberg P; Meulenbeld HJ; De Laere B; Dirix LY; van Soest RJ; Lolkema MP; Martens JW; van Weerden WM; Jenster GW; Foekens JA; de Wit R; Sleijfer S
Eur Urol; 2015 Dec; 68(6):939-45. PubMed ID: 26188394
[TBL] [Abstract][Full Text] [Related]
30. In Situ Detection and Quantification of AR-V7, AR-FL, PSA, and
El-Heliebi A; Hille C; Laxman N; Svedlund J; Haudum C; Ercan E; Kroneis T; Chen S; Smolle M; Rossmann C; Krzywkowski T; Ahlford A; Darai E; von Amsberg G; Alsdorf W; König F; Löhr M; de Kruijff I; Riethdorf S; Gorges TM; Pantel K; Bauernhofer T; Nilsson M; Sedlmayr P
Clin Chem; 2018 Mar; 64(3):536-546. PubMed ID: 29301749
[TBL] [Abstract][Full Text] [Related]
31. Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts.
Lorente D; Olmos D; Mateo J; Dolling D; Bianchini D; Seed G; Flohr P; Crespo M; Figueiredo I; Miranda S; Scher HI; Terstappen LWMM; de Bono JS
Ann Oncol; 2018 Jul; 29(7):1554-1560. PubMed ID: 29741566
[TBL] [Abstract][Full Text] [Related]
32. Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial.
Larsson AM; Jansson S; Bendahl PO; Levin Tykjaer Jörgensen C; Loman N; Graffman C; Lundgren L; Aaltonen K; Rydén L
Breast Cancer Res; 2018 Jun; 20(1):48. PubMed ID: 29884204
[TBL] [Abstract][Full Text] [Related]
33. The Added Value of Circulating Tumor Cell Enumeration to Standard Markers in Assessing Prognosis in a Metastatic Castration-Resistant Prostate Cancer Population.
Heller G; Fizazi K; McCormack R; Molina A; MacLean D; Webb IJ; Saad F; de Bono JS; Scher HI
Clin Cancer Res; 2017 Apr; 23(8):1967-1973. PubMed ID: 27678453
[No Abstract] [Full Text] [Related]
34. Gene Expression Alterations during Development of Castration-Resistant Prostate Cancer Are Detected in Circulating Tumor Cells.
Josefsson A; Larsson K; Freyhult E; Damber JE; Welén K
Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31877738
[TBL] [Abstract][Full Text] [Related]
35. Circulating Tumor Cells as a Biomarker of Survival and Response to Radium-223 Therapy: Experience in a Cohort of Patients With Metastatic Castration-Resistant Prostate Cancer.
Carles J; Castellano D; Méndez-Vidal MJ; Mellado B; Saez MI; González Del Alba A; Perez-Gracia JL; Jimenez J; Suárez C; Sepúlveda JM; Manneh R; Porras I; López C; Morales-Barrera R; Arranz JÁ
Clin Genitourin Cancer; 2018 Dec; 16(6):e1133-e1139. PubMed ID: 30104161
[TBL] [Abstract][Full Text] [Related]
36. Prostate-specific membrane antigen in circulating tumor cells is a new poor prognostic marker for castration-resistant prostate cancer.
Nagaya N; Nagata M; Lu Y; Kanayama M; Hou Q; Hotta ZU; China T; Kitamura K; Matsushita K; Isotani S; Muto S; Sakamoto Y; Horie S
PLoS One; 2020; 15(1):e0226219. PubMed ID: 31986176
[TBL] [Abstract][Full Text] [Related]
37. Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort.
Jansson S; Bendahl PO; Larsson AM; Aaltonen KE; Rydén L
BMC Cancer; 2016 Jul; 16():433. PubMed ID: 27390845
[TBL] [Abstract][Full Text] [Related]
38. Associations between AR-V7 status in circulating tumour cells, circulating tumour cell count and survival in men with metastatic castration-resistant prostate cancer.
Belderbos BPS; Sieuwerts AM; Hoop EO; Mostert B; Kraan J; Hamberg P; Van MN; Beaufort CM; Onstenk W; van Soest RJ; Martens J; Sleijfer S; de Wit R; Mathijssen RHJ; Lolkema MP
Eur J Cancer; 2019 Nov; 121():48-54. PubMed ID: 31542641
[TBL] [Abstract][Full Text] [Related]
39. Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial.
Jueckstock J; Rack B; Friedl TW; Scholz C; Steidl J; Trapp E; Tesch H; Forstbauer H; Lorenz R; Rezai M; Häberle L; Alunni-Fabbroni M; Schneeweiss A; Beckmann MW; Lichtenegger W; Fasching PA; Pantel K; Janni W;
BMC Cancer; 2016 Jul; 16():401. PubMed ID: 27387743
[TBL] [Abstract][Full Text] [Related]
40. Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer.
Mu Z; Wang C; Ye Z; Austin L; Civan J; Hyslop T; Palazzo JP; Jaslow R; Li B; Myers RE; Jiang J; Xing J; Yang H; Cristofanilli M
Breast Cancer Res Treat; 2015 Dec; 154(3):563-71. PubMed ID: 26573830
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
